« Back to Record
Citation APA

Journé, F., Durbecq, V., Haibe-Kains, B., Chaboteaux, C., Rouas, G., Laurent, G., Larsimont, D., Piccart-Gebhart, M., Body, J.-J., & Sotiriou, C. (2008). Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. European journal of cancer, 6(7), Suppl, Abstr 218 (EBCC-6), 112. doi:10.1016/S1359-6349(08)70534-2


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/70703

Journé, F., Durbecq, V., Haibe-Kains, B., Chaboteaux, C., Rouas, G., Laurent, G., Larsimont, D., Piccart-Gebhart, M., Body, J.-J., & Sotiriou, C. (2008). Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. European journal of cancer, 6(7), Suppl, Abstr 218 (EBCC-6), 112. doi:10.1016/S1359-6349(08)70534-2